Trial Profile
A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms METASUN
- 18 Mar 2021 Status changed from active, no longer recruiting to discontinued due to not enough accrual.
- 05 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 23 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.